Deep Sequencing of HIV: Clinical and Research Applications

被引:27
作者
Chabria, Shiven B. [1 ]
Gupta, Shaili [1 ,2 ]
Kozal, Michael J. [1 ,2 ]
机构
[1] Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, New Haven, CT 06510 USA
[2] VA Connecticut Healthcare Syst, Dept Internal Med, Sect Infect Dis, West Haven, CT 06516 USA
来源
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 15 | 2014年 / 15卷
关键词
HIV quasispecies; transmitted drug resistance; mutant variants; low-frequency variants; deep sequencing; IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG-RESISTANCE MUTATIONS; REVERSE-TRANSCRIPTASE INHIBITORS; ACTIVE ANTIRETROVIRAL THERAPY; TREATMENT-NAIVE INDIVIDUALS; MINORITY VARIANTS; RISK-FACTORS; GENETIC-CHARACTERIZATION; NEUTRALIZING ANTIBODIES; HIV-1-INFECTED PATIENTS;
D O I
10.1146/annurev-genom-091212-153406
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Human immunodeficiency virus (HIV) exhibits remarkable diversity in its genomic makeup and exists in any given individual as a complex distribution of closely related but nonidentical genomes called a viral quasispecies, which is subject to genetic variation, competition, and selection. This viral diversity clinically manifests as a selection of mutant variants based on viral fitness in treatment-naive individuals and based on drug-selective pressure in those on antiretroviral therapy (ART). The current standard-of-care ART consists of a combination of antiretroviral agents, which ensures maximal viral suppression while preventing the emergence of drug-resistant HIV variants. Unfortunately, transmission of drug-resistant HIV does occur, affecting 5% to >20% of newly infected individuals. To optimize therapy, clinicians rely on viral genotypic information obtained from conventional population sequencing-based assays, which cannot reliably detect viral variants that constitute <20% of the circulating viral quasispecies. These low-frequency variants can be detected by highly sensitive genotyping methods collectively grouped under the moniker of deep sequencing. Low-frequency variants have been correlated to treatment failures and HIV transmission, and detection of these variants is helping to inform strategies for vaccine development. Here, we discuss the molecular virology of HIV, viral heterogeneity, drug-resistance mutations, and the application of deep sequencing technologies in research and the clinical care of HIV-infected individuals.
引用
收藏
页码:295 / 325
页数:31
相关论文
共 157 条
[1]   Substantial Multiclass Transmitted Drug Resistance and Drug-Relevant Polymorphisms Among Treatment-Naive Behaviorally HIV-Infected Youth [J].
Agwu, Allison L. ;
Bethel, James ;
Hightow-Weidman, Lisa B. ;
Sleasman, John W. ;
Wilson, Craig M. ;
Rudy, Bret ;
Kapogiannis, Bill G. .
AIDS PATIENT CARE AND STDS, 2012, 26 (04) :193-196
[2]   Rates of transmission of antiretroviral drug resistant strains of HIV-1 [J].
Ammaranond, P ;
Cunningham, P ;
Oelrichs, R ;
Suzuki, K ;
Harris, C ;
Leas, L ;
Grulich, A ;
Cooper, DA ;
Kelleher, AD .
JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (02) :153-161
[3]   Reconstituting the Epidemic History of HIV Strain CRF01_AE among Men Who Have Sex with Men (MSM) in Liaoning, Northeastern China: Implications for the Expanding Epidemic among MSM in China [J].
An, Minghui ;
Han, Xiaoxu ;
Xu, Junjie ;
Chu, Zhenxing ;
Jia, Manhong ;
Wu, Hao ;
Lu, Lin ;
Takebe, Yutaka ;
Shang, Hong .
JOURNAL OF VIROLOGY, 2012, 86 (22) :12402-12406
[4]  
[Anonymous], 2013, GUID US ANT AG HIV 1
[5]  
[Anonymous], JC25021E UNAIDS
[6]   Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing [J].
Armenia, Daniele ;
Vandenbroucke, Ina ;
Fabeni, Lavinia ;
Van Marck, Herwig ;
Cento, Valeria ;
D'Arrigo, Roberta ;
Van Wesenbeeck, Liesbeth ;
Scopelliti, Fernanda ;
Micheli, Valeria ;
Bruzzone, Bianca ;
Lo Caputo, Sergio ;
Aerssens, Jeroen ;
Rizzardini, Giuliano ;
Tozzi, Valerio ;
Narciso, Pasquale ;
Antinori, Andrea ;
Stuyver, Lieven ;
Perno, Carlo Federico ;
Ceccherini-Silberstein, Francesca .
JOURNAL OF INFECTIOUS DISEASES, 2012, 205 (04) :557-567
[7]   Antibody gene transfer for HIV immunoprophylaxis [J].
Alejandro B Balazs ;
Anthony P West .
Nature Immunology, 2013, 14 (1) :1-5
[8]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[9]   A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-Week virologic results of ACTG A5086 [J].
Benson, Constance A. ;
Vaida, Florin ;
Havlir, Diane V. ;
Downey, Gerald F. ;
Lederman, Michael M. ;
Gulick, Roy M. ;
Glesby, Marshall J. ;
Wantman, Michael ;
Bixby, Christian J. ;
Rinehart, Alex R. ;
Snyder, Sally ;
Wang, Rui ;
Patel, Sheran ;
Mellors, John W. .
JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (09) :1309-1318
[10]   Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C [J].
Binley, James M. ;
Lybarger, Elizabeth A. ;
Crooks, Emma T. ;
Seaman, Michael S. ;
Gray, Elin ;
Davis, Katie L. ;
Decker, Julie M. ;
Wycuff, Diane ;
Harris, Linda ;
Hawkins, Natalie ;
Wood, Blake ;
Nathe, Cory ;
Richman, Douglas ;
Tomaras, Georgia D. ;
Bibollet-Ruche, Frederic ;
Robinson, James E. ;
Morris, Lynn ;
Shaw, George M. ;
Montefiori, David C. ;
Mascola, John R. .
JOURNAL OF VIROLOGY, 2008, 82 (23) :11651-11668